Angio-3 for treatment of retinal angiogenic diseases

Abstract

This disclosure provides methods of a method of treating a retinal angiogenic disease in a subject comprising administering an effective amount of an Angio-3 peptide.

1 .- 24 . (canceled) 
     
     
         25 . A method of treating a retinal angiogenic disease in a subject comprising:
 (a) selecting a subject with retinal angiogenic disease not responsive to anti-VEGF therapy; and   (b) administering to the subject a composition comprising a peptide consisting of the sequence Thr Pro His Thr His Gin Xaa Thr Pro Glu (SEQ ID NO:4) wherein administration treats the retinal angiogenic disease in the subject.   
     
     
         26 . The method of  claim 25 , wherein the composition comprises 2 to 50 mg/kg Bwt of the peptide and is administered by intravenous injection. 
     
     
         27 . The method of  claim 25 , wherein the composition comprises 0.1 μg/kg to 2 mg/kg Bwt of the peptide and is administered by intravitreal injection. 
     
     
         28 . The method of  claim 25 , wherein the composition comprises 2 to 10 mg/kg Bwt of the peptide and is administered orally. 
     
     
         29 . The method of  claim 25 , wherein the composition is administered via either intravenous (IV) or intravitreal (IVT) route at least once every 4 to 10 weeks. 
     
     
         30 . The method of  claim 25 , wherein the composition is administered orally at least once daily for 1 to 2 weeks at intervals of 6 months. 
     
     
         31 . The method of  claim 25 , wherein the anti-VEGF therapy is an anti-VEGF antibody. 
     
     
         32 . The method of  claim 25 , wherein the subject has age-related macular degeneration, retinopathy, or vascular occlusion. 
     
     
         33 . The method of  claim 25 , wherein the subject has diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, or corneal neovascularization. 
     
     
         34 . The method of  claim 25 , wherein the subject is a human. 
     
     
         35 . The method of  claim 25 , wherein the composition is formulated for intravenous administration. 
     
     
         36 . The method of  claim 25 , wherein the composition is formulated for intravitreal injection. 
     
     
         37 . The method of  claim 25 , wherein the composition is formulated for oral administration.